Board of Directors

Born: 1964

Mr. Kronborg has extensive financial and leadership experience spanning more than 30 years. Mr. Kronborg is currently CEO at ResoTher Pharma as well as a board member at the Swedish Biotec company Aqilion. Mr. Kronborg holds a Master of Economics and spent close to 10 years in the Ministry of Finance – ending as head of department. From 1996-2007, Mr. Kronborg held different positions as CEO or CFO in different Danish media companies. In 2007, he joined the Swedish investment company Kinnevik AB. From 2012-2015 he was COO for the entire group. Mr. Kronborg then moved to the Pharma Industry – from 2015-2022 he served as CFO and interim CEO at LEO Pharma – a Danish company with a turnover of more than SEK 10 billion – spending his time growing the company through several M&A activities.

Independent in relation to the company and the company management: No

Independent in relation to the major shareholders: Yes

Holdings: See this page for updated holdings

Born: 1980

Mr. Andersen has extensive financial and leadership experience spanning around 20 years. He is currently the Group CEO of Sanos Group A/S, a global multi-niche CRO with full service clinical capabilities. Mr. Andersen is also board member in Arctic Therapeutics (IS) and CEO of NBCD A/S (part of Sanos Group).

Mr. Andersen has a Master of Science in Pharmacy from Copenhagen University and a Master of Business Administration from Quantic School of Business and Technology, Washington, US, and extensive experience in management of clinical trials and associated companies.

Independent in relation to the company and the company management: Yes

Independent in relation to major shareholders: No

Shareholding in SynAct: Jeppe Ragnar Andersen holds 500 shares directly in SynAct Pharma and owns 1.3% per cent of the shares in Sanos Group which owns NBCD A/S. NBCD A/S holds shares in SynAct Pharma AB.

See this page for updated holdings.

Born: 1951

Mr. Scheibye has a long career in pharma and med-tech, where he has been active for over 30 years. He has held positions such as medical sales rep, medical registration officer dealing with FDA as well as EU authorities. Later he moved into commercial roles and senior leadership positions. For 13 years Mr. Scheibye was CEO of the Danish, listed company Coloplast. During his tenure, Coloplast 6-doubled turnover and 8-doubled share performance. Later Mr. Scheibye has focused on board positions where he has held numerous in private as well as public entities. Mr. Scheibye has served as chairman of Novo Nordisk A/S where he had a seat on the board for 10 years until he became chairman of the Novo Nordisk Foundation and Novo Holdings. Mr. Scheibye has a PhD in organic chemistry from Aarhus University and a B.Com. from Copenhagen Business School.

Independent in relation to the company and the company management: Yes

Independent in relation to the major shareholders: Yes

Holdings: See this page for updated holdings

Born: 1959

Mr. Sørensen has extensive leadership experience in the pharmaceutical and biotech industries spanning over 430 years. Mr. Sørensen is currently CEO and board member of the clinical stage biotech company Cereno Scientific, a company which he joined as a board member 2014 and assumed the CEO role in 2015 when the company was still privately held and in early an early project stage. Under Mr. Sørensen’s leadership, the Ccompany has been propelled into a promising three candidate drug pipeline, all potentially ground breaking therapies in rare and common cardiovascular and pulmonary diseases with high unmet needs. Cereno is listed at NFGM with a current MCAp of caapprox. SEK 3,21 billion. Prior toBefore Cereno, Mr. Sørensen has held senior positions in major pharma including Head of International Marketing Operations for SEK 10 billion pharma portfolio at Monsanto (GD Searle, Chicago, US) and Global Marketing Director for the SEK 4 billion portfolio of Secondary Prevention Products, Cardiovasculars at AstraZeneca (Gbg, Sweden). Mr. Sørensen has during his career iat Monsanto and AstraZeneca successfully pursuedinitiated two groundbreaking preventive survival studies in heart failure, with an MR antagonist (spironolactone) and a betablocker (metoprolol) respectively. Mr. Sørensen is Chairman of SARomics Biostructures since 2013. Mr. Sørensen holds a bachelor’s degree in chemistry from Lund University.

Independent in relation to the company and the company management: No

Independent in relation to the major shareholders: Yes

Holdings: See this page for updated holdings